Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 10/20 | 0.38 |
| ▸ | ATXN2 | Q99700 | 5/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | RBP4 | P02753 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16963581 | 1.00 | FASN (0.38) | FASNATXN2EGLN1RBP4ENPP2 | |
| SCHEMBL16963579 | 1.00 | FASN (0.38) | FASNATXN2EGLN1RBP4ENPP2 | |
| SCHEMBL16961966 | 0.89 | MAPT (0.43) | FASN | |
| SCHEMBL16961961 | 0.89 | MAPT (0.43) | FASN | |
| SCHEMBL16963265 | 0.89 | FASN (0.40) | FASNATXN2EGLN1DGAT2 | |
| SCHEMBL21323390 | 0.89 | FASN (0.40) | FASNATXN2EGLN1DGAT2 | |
| SCHEMBL16963263 | 0.89 | FASN (0.40) | FASNATXN2EGLN1DGAT2 | |
| SCHEMBL21322953 | 0.88 | ATXN2 (0.45) | FASNATXN2EGLN1ENPP2 | |
| SCHEMBL16963212 | 0.88 | ATXN2 (0.45) | FASNATXN2EGLN1ENPP2 | |
| SCHEMBL16963210 | 0.88 | ATXN2 (0.45) | FASNATXN2EGLN1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900669-B1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | disclosed |